Table 1.
Characteristics of patients who underwent first allogeneic transplantation with an HLA- identical sibling or unrelated donor for AML in CR1 and received preparation with Cy/TBI, oral or IV BuCy, reported to CIBMTR from 2000 to 2006
| Characteristics of patients | Cy/TBI | Oral BuCy | IV BuCy |
|---|---|---|---|
| Number of patients | 586 | 408 | 236 |
| Number of centers | 117 | 86 | 80 |
| Patient-related | |||
| Age, median (range), years | 37 (2-63) | 34 (2-62) | 40 (2-64) |
| 10 y or less | 17 (3) | 26 (6) | 27 (11) |
| 11-20 | 66 (11) | 65 (16) | 35 (15) |
| 21-30 | 110 (19) | 88 (22) | 29 (12) |
| 31-40 | 144 (25) | 80 (20) | 31 (13) |
| 41-50 | 159 (27) | 97 (24) | 65 (28) |
| Older than 50 | 90 (15) | 52 (13) | 49 (21) |
| Sex | |||
| Male | 307 (52) | 216 (53) | 122 (52) |
| Karnofsky score at transplant | |||
| Less than 90% | 128 (22) | 56 (14) | 51 (22) |
| Greater than or equal to 90% | 424 (72) | 340 (83) | 174 (74) |
| Missing | 34 (6) | 12 (3) | 11 (5) |
| Disease-related Cytogenetic classification34 | |||
| Favorable | 25 (4) | 24 (6) | 16 (7) |
| Intermediate | 244 (42) | 230 (56) | 117 (50) |
| Poor | 215 (37) | 135 (33) | 81 (34) |
| Missing | 102 (17) | 19 (5) | 22 (9) |
| Transplant-related | |||
| Time from diagnosis to transplant, median (range), months | 5 (2-44) | 5 (2-49) | 5 (2-25) |
| Donor-recipient sex match | |||
| Male - male | 198 (34) | 123 (30) | 72 (31) |
| Female - male | 109 (19) | 93 (23) | 49 (21) |
| Male - female | 152 (26) | 110 (27) | 67 (28) |
| Female - female | 126 (22) | 82 (20) | 47 (20) |
| Missing | 1 (<1) | 0 | 1 (<1) |
| Donor-recipient HLA match39 | |||
| HLA-identical sibling | 229 (39) | 309 (76) | 111 (47) |
| Well-matched URD | 268 (46) | 72 (18) | 99 (42) |
| Partially matched URD | 68 (12) | 23 (6) | 23 (10) |
| Mismatched URD | 21 (4) | 4 (<1) | 3 (1) |
| Donor-recipient CMV serology | |||
| +/+ | 160 (27) | 86 (21) | 60 (25) |
| +/− | 181 (31) | 202 (50) | 87 (37) |
| −/+ | 73 (12) | 32 (8) | 24 (10) |
| −/− | 145 (25) | 76 (19) | 58 (25) |
| Missing | 27 (5) | 12 (3) | 7 (3) |
| HLA-identical sibling donor age, median (range), years | 38 (4-66) | 30 (2-71) | 36 (3-63) |
| Unrelated donor age, median (range), years | 34 (19-58) | 35 (19-56) | 33 (19-59) |
| Graft type | |||
| Bone Marrow | 231 (39) | 165 (40) | 108 (46) |
| Peripheral blood | 355 (61) | 243 (60) | 128 (54) |
| Conditioning regimen | |||
| BuCy | 0 | 408 | 236 |
| Bu dose, median (range), mg/kg | 0 | 16 (9-27) | 13 (9-21) |
| Cy/TBI (nonfractionated 550-750) | 34 (6) | 0 | 0 |
| Cy/TBI (nonfractionated 800-1200) | 12 (2) | 0 | 0 |
| Cy/TBI (fractionated 900-1170) | 16 (3) | 0 | 0 |
| Cy/TBI (fractionated 1200-1300) | 322 (55) | 0 | 0 |
| Cy/TBI (fractionated 1320-1395) | 144 (25) | 0 | 0 |
| Cy/TBI (fractionated 1400-1500) | 58 (10) | 0 | 0 |
| ATG and Alemtuzumab usage | |||
| ATG | 56 (10) | 40 (10) | 43 (18) |
| Alemtuzumab | 2 (<1) | 1 (<1) | 5 (2) |
| Missing | 1 (<1) | 2 (<1) | 0 |
| GVHD prophylaxis | |||
| TAC + MMF ± others | 26 (4) | 4 (<1) | 5 (2) |
| TAC + MTX ± others (except MMF) | 186 (32) | 43 (11) | 79 (33) |
| TAC ± others (except MTX, MMF) | 17 (3) | 4 (<2) | 9 (4) |
| CSA + MMF ± others (except TAC) | 8 (1) | 10 (2) | 3 (1) |
| CSA + MTX ± others (except TAC, MMF) | 312 (53) | 313 (77) | 118 (50) |
| CSA ± others (except TAC, MTX, MMF) | 28 (4) | 18 (5) | 14 (6) |
| Other GVHD prophylaxis | 3 (<1) | 11 (3) | 6 (3) |
| Missing | 6 (1) | 5 (1) | 2 (<1) |
| Growth factors given posttransplant: G-CSF or GM-CSF | |||
| No | 472 (81) | 299 (73) | 166 (70) |
| Yes | 112 (19) | 109 (27) | 70 (30) |
| Missing | 2 (<1) | 0 | 0 |
| Year of transplant | |||
| 2000 | 69 (12) | 46 (11) | 8 (3) |
| 2001 | 72 (12) | 52 (13) | 5 (2) |
| 2002 | 69 (12) | 63 (15) | 16 (7) |
| 2003 | 63 (11) | 64 (16) | 23 (10) |
| 2004 | 107 (18) | 73 (18) | 54 (23) |
| 2005 | 113 (19) | 54 (13) | 74 (31) |
| 2006 | 93 (16) | 56 (14) | 56 (24) |
| Median follow-up of survivors, (range) months | 68 (3-137) | 57 (2-124) | 59 (3-120) |
ATG, antithymocyte globulin; CSA, cyclosporine; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; MMF, mycophenolate; MTX, methotrexate; and TAC, tacrolimus